Sep 12, 2005 by Brian GormanFord's Italian AffairThe Ford-Fiat alliance may be part of a larger trend investors should keep an eye on.
Sep 12, 2005 by Brian GormanMixed Diagnosis for Bristol-MyersPositive news on two drugs is reason to celebrate, but investors may want to keep their enthusiasm in check.
Jul 7, 2005 by Brian GormanLet's Grab a Burger, Where?The company behind Hardee's and Carl's Jr. chains is concentrating on markets below the radar. It's a stategy worth watching.
Jul 6, 2005 by Brian GormanMcDonald's New DudsThe fast food company's plan to remake its uniforms is money well spent.
Jul 6, 2005 by Brian GormanFord Jumps on the Bandwagon With GMFord may find it harder to abandon the current round of incentives than its rival GM.
Jul 5, 2005 by Brian GormanBausch & Lomb Eyes ChinaThe firm's latest purchase will add geographic diversity to its pharmaceutical business.
Jul 1, 2005 by Brian GormanFord Links Up With BPThe deal makes sense, but the impact will be minimal as long as rivals outmaneuver the automaker.
Jun 30, 2005 by Brian GormanThe Co-Pay EffectHigher co-payments look like the wave of the future, and that should mean brisk business for the right makers of generic drugs.
Jun 30, 2005 by Brian GormanTeva's Non-Generic SideThe drug company is working hard to cement its position in the market for multiple sclerosis meds.
Jun 29, 2005 by Brian GormanJarden of Eatin'Jarden continues its buying spree. So far, the strategy is working well.
Jun 28, 2005 by Brian GormanCardinal Changes CourseThe company's warning is a disappointment, but the firm's new focus on returning cash to shareholders is far from bad news.
Jun 28, 2005 by Brian GormanStarbucks Nabs DylanThe coffee outfit's exclusive deal to sell a Bob Dylan album illustrates the continued potential of the firm's strategy.
Jun 27, 2005 by Brian GormanPfizer's Controversial PairingThe company's strategy of combining an experimental medicine with Lipitor will likely come under increasing fire.
Jun 27, 2005 by Brian GormanAlkermes' Powerful PartnershipThe deal should bring strong sales and valuable experience.
Jun 24, 2005 by Brian GormanBroken CovenantTrucker has a tough road ahead, but also some saving graces.
Jun 24, 2005 by Brian GormanSalix's Strange DealThe company's acquisition of Inkine hardly seems wise.
Jun 23, 2005 by Brian GormanAmgen's Drug-Approval DilemmaA recent lawsuit illustrates drugmakers' difficult position.
Jun 22, 2005 by Brian GormanScion RisingThe youth-targeted Scion may be the most powerful weapon Toyota has as it grows its market share in the U.S.
Jun 22, 2005 by Brian GormanBiotech's Global AgendaBristol-Myers' recent outsourcing deal illustrates the global spread of biotech investments.
Jun 21, 2005 by Brian GormanWyeth's Lower DosageThe company's planned sales-force cutback shows its resolve to increase efficiency.
